<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="310">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <actrnumber>ACTRN12605000363684</actrnumber>
  <trial_identification>
    <studytitle>N-acetyl cysteine in schizophrenia: A double blind randomised placebo controlled trial</studytitle>
    <scientifictitle>N-acetyl cysteine in Schizophrenia:A double blind randomised placebo 
controlled trial investigating a range of psychiatric rating scales</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a six month study with a four to six week post-disconinuation visit.  The trial involves taking 2g of n-acetyl cysteine per day in addition to the participant's usual treatment.</interventions>
    <comparator>Placebo </comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PANSS</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>GAF</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>SOFAS</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CGI</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cognitive testing</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assessment of involuntary movements</outcome>
      <timepoint>Used at each of the 10 visits over a 6 month period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety data such as blood pressure, BMI, and routine blood testing.</outcome>
      <timepoint>Blood pressure and BMI are taken at each visit whereas blood collection/testing is carried out at baseline and two months into the trial.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DSM-IV diagnosis of schizophrenia, have a PANSS score of &gt;55 or at least two items in the positive and/or negative items being &gt;3 AND/OR have a CGI-S &gt;3, be utilising effective contraception if of child-bearing age.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Taking mood stabilisers, asthma or history of respiratory insufficiency/allergy to n-acetyl cysteine, abnormal heamotological findings, or systemic medical disorder, currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day or inability to comply with the informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/01/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Stanley Medical Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Stanley Medical Research Institute Grant</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Mental Health Research Institute</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Health Care Group</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lausanne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ballarat Health Services</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South West Area Mental Health Service (Werribee)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Michael Berk</name>
      <address>The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52603154</phone>
      <fax />
      <email>mikebe@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Olivia Dean</name>
      <address>The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52267428</phone>
      <fax />
      <email>odean@mhri.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>